Outlook Therapeutics, Inc.
OTLK
$1.45
$0.085.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -46.81M | -75.37M | -94.05M | -159.13M | -51.50M |
| Total Depreciation and Amortization | 114.50K | 113.90K | 96.30K | 78.80K | 61.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.10M | 9.48M | 38.63M | 105.11M | 10.24M |
| Change in Net Operating Assets | 8.07M | -3.02M | -9.23M | -4.31M | -5.91M |
| Cash from Operations | -66.73M | -68.79M | -64.55M | -58.26M | -47.10M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -1.10K | -4.30K | -7.40K | -10.40K | -12.20K |
| Issuance of Common Stock | 62.19M | 60.45M | 62.88M | 61.87M | 5.73M |
| Repurchase of Common Stock | -115.00K | -115.00K | -- | -- | -339.30K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | -255.00K |
| Cash from Financing | 62.07M | 60.33M | 62.87M | 61.86M | 5.12M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.65M | -8.46M | -1.68M | 3.60M | -41.98M |